Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HFB200301 |
Synonyms | |
Therapy Description |
HFB200301 is an antibody that targets TNFR2, potentially resulting in enhanced anti-tumor immune response (Cancer Res (2021) 81 (13_Supplement): 1883). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HFB200301 | HFB 200301|HFB-200301 | HFB200301 is an antibody that targets TNFR2, potentially resulting in enhanced anti-tumor immune response (Cancer Res (2021) 81 (13_Supplement): 1883). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05238883 | Phase I | HFB200301 HFB200301 + Tislelizumab | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Recruiting | USA | ESP | 0 |